Tyrosine kinase inhibitor-induced immune hemolytic anemia; three different drugs in three separate cases.

TKIs are relatively new in clinical practice and are being used for more indications and in more patients. To our knowledge#these three cases are unique in terms of axitinib#sunitinib#and pazopanib-related IHA.